156 related articles for article (PubMed ID: 38365354)
1. Irreversible electroporation: Beyond the limits of tumor ablation.
Alonso-González R; Abadal Villayandre JM; Gálvez Gonzalez E; Álvarez Perez MJ; Méndez Alonso S; de Gregorio Ariza MA
Radiologia (Engl Ed); 2024; 66(1):47-56. PubMed ID: 38365354
[TBL] [Abstract][Full Text] [Related]
2. Irreversible Electroporation in Hepatopancreaticobiliary Tumours.
Ruarus AH; Vroomen LGPH; Puijk RS; Scheffer HJ; Zonderhuis BM; Kazemier G; van den Tol MP; Berger FH; Meijerink MR
Can Assoc Radiol J; 2018 Feb; 69(1):38-50. PubMed ID: 29458954
[TBL] [Abstract][Full Text] [Related]
3. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study.
Scheffer HJ; Nielsen K; van Tilborg AA; Vieveen JM; Bouwman RA; Kazemier G; Niessen HW; Meijer S; van Kuijk C; van den Tol MP; Meijerink MR
Eur Radiol; 2014 Oct; 24(10):2467-75. PubMed ID: 24939670
[TBL] [Abstract][Full Text] [Related]
4. [Irreversible electroporation: local, non-thermal, ablation therapy of malignant tumours].
Janík V; Skrabalová D; Gürlich R; Málek J
Cas Lek Cesk; 2013; 152(2):67-75. PubMed ID: 23641678
[TBL] [Abstract][Full Text] [Related]
5. New Developments in Image-Guided Percutaneous Irreversible Electroporation of Solid Tumors.
Yun JH; Fang A; Khorshidi F; Habibollahi P; Kutsenko O; Etezadi V; Hunt S; Nezami N
Curr Oncol Rep; 2023 Nov; 25(11):1213-1226. PubMed ID: 37695398
[TBL] [Abstract][Full Text] [Related]
6. [Irreversible electroporation: local tumor ablation with systemic immune effect].
Geboers B; Timmer FEF; van den Tol PM; de Gruijl TD; Scheffer HJ; Meijerink MR
Ned Tijdschr Geneeskd; 2021 Sep; 165():. PubMed ID: 34854585
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous irreversible electroporation of a renal tumor: Anesthetic management.
de la Flor-Robledo M; Solís-Muñoz P; Sanjuán-Álvarez M; Abadal-Villayandre JM; Asensio-Merino F
Rev Esp Anestesiol Reanim; 2016; 63(7):419-22. PubMed ID: 26874983
[TBL] [Abstract][Full Text] [Related]
8. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).
Wendler JJ; Pech M; Fischbach F; Jürgens J; Friebe B; Baumunk D; Porsch M; Blaschke S; Schindele D; Siedentopf S; Ricke J; Schostak M; Köllermann J; Liehr UB
Urology; 2018 Apr; 114():224-232. PubMed ID: 29305201
[TBL] [Abstract][Full Text] [Related]
9. [Irreversible electroporation: a new form of image-guided tumour ablation].
Scheffer H; Nielsen K; van Tilborg A; Vieveen JM; van den Tol MP; Meijerink MR
Ned Tijdschr Geneeskd; 2014; 158():A7176. PubMed ID: 24518847
[TBL] [Abstract][Full Text] [Related]
10. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
[TBL] [Abstract][Full Text] [Related]
11. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
[TBL] [Abstract][Full Text] [Related]
12. Application of Irreversible Electroporation Ablation as Adjunctive Treatment for Margin Enhancement: Safety and Efficacy.
Simmerman E; Chung J; Lawson A; Kruse E
J Surg Res; 2020 Feb; 246():260-268. PubMed ID: 31610354
[TBL] [Abstract][Full Text] [Related]
13. The Enlargement of Ablation Area by Electrolytic Irreversible Electroporation (E-IRE) Using Pulsed Field with Bias DC Field.
Lv Y; Liu H; Feng Z; Zhang J; Chen G; Yao C
Ann Biomed Eng; 2022 Dec; 50(12):1964-1973. PubMed ID: 35852648
[TBL] [Abstract][Full Text] [Related]
14. Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors.
Zhang N; Li Z; Han X; Zhu Z; Li Z; Zhao Y; Liu Z; Lv Y
Front Immunol; 2021; 12():811726. PubMed ID: 35069599
[TBL] [Abstract][Full Text] [Related]
15. [Irreversible electroporation: present and future in the treatment of hepatocellular carcinoma].
Cano D; Lasarte JJ; Vivas I
An Sist Sanit Navar; 2022 Nov; 45(3):. PubMed ID: 36413004
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model.
Dunki-Jacobs EM; Philips P; Martin RC
Br J Surg; 2014 Aug; 101(9):1113-21. PubMed ID: 24961953
[TBL] [Abstract][Full Text] [Related]
17. Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.
Wendler JJ; Ganzer R; Hadaschik B; Blana A; Henkel T; Köhrmann KU; Machtens S; Roosen A; Salomon G; Sentker L; Witzsch U; Schlemmer HP; Baumunk D; Köllermann J; Schostak M; Liehr UB
World J Urol; 2017 Jan; 35(1):11-20. PubMed ID: 27147512
[TBL] [Abstract][Full Text] [Related]
18. Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation.
Zhang Z; Li W; Procissi D; Tyler P; Omary RA; Larson AC
Nanomedicine (Lond); 2014; 9(8):1181-92. PubMed ID: 24024571
[TBL] [Abstract][Full Text] [Related]
19. Anaesthetic management during open and percutaneous irreversible electroporation.
Nielsen K; Scheffer HJ; Vieveen JM; van Tilborg AA; Meijer S; van Kuijk C; van den Tol MP; Meijerink MR; Bouwman RA
Br J Anaesth; 2014 Dec; 113(6):985-92. PubMed ID: 25173767
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
